3:I[2885,["231","static/chunks/231-9e11bdfe3b664aec.js","669","static/chunks/app/asx/%5Bticker%5D/page-c5ee851f99e4cbe6.js"],"default"]
4:I[231,["231","static/chunks/231-9e11bdfe3b664aec.js","669","static/chunks/app/asx/%5Bticker%5D/page-c5ee851f99e4cbe6.js"],""]
5:I[9275,[],""]
7:I[1343,[],""]
8:I[8173,["231","static/chunks/231-9e11bdfe3b664aec.js","896","static/chunks/896-78f6f35c40d7ae60.js","185","static/chunks/app/layout-24f8abeacb8025a3.js"],"Image"]
9:I[5864,["231","static/chunks/231-9e11bdfe3b664aec.js","896","static/chunks/896-78f6f35c40d7ae60.js","185","static/chunks/app/layout-24f8abeacb8025a3.js"],"default"]
2:T5f2,{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What does NYR do?","acceptedAnswer":{"@type":"Answer","text":"Nyrada Inc. is a biotechnology company developing novel drug candidates for serious medical conditions. Their primary focus areas are neuroprotection, with a lead program for traumatic brain injury and stroke, and cardiovascular disease, addressing unmet medical needs with potential first-in-class treatments."}},{"@type":"Question","name":"Is NYR a good investment?","acceptedAnswer":{"@type":"Answer","text":"Investing in Nyrada is considered highly speculative due to its early-stage drug development pipeline and pre-revenue status. It offers significant upside potential if its clinical trials prove successful and lead to commercialization or partnerships, but also carries high risks of failure common to the biotech sector. Investors should be prepared for volatility and the possibility of substantial capital loss."}},{"@type":"Question","name":"What drives NYR's share price?","acceptedAnswer":{"@type":"Answer","text":"Nyrada's share price is primarily driven by news related to its clinical trial progress, such as commencement of new trial phases, interim or final data readouts, and regulatory milestones (e.g., ethics approvals, IND filings). Other key drivers include announcements of capital raises, strategic partnerships or licensing agreements, and general investor sentiment towards the biotechnology sector and specific therapeutic areas."}}]}6:["ticker","NYR","d"]
0:["uKIfBFgUIiWYAPP8_HSuj",[[["",{"children":["asx",{"children":[["ticker","NYR","d"],{"children":["__PAGE__?{\"ticker\":\"NYR\"}",{}]}]}]},"$undefined","$undefined",true],["",{"children":["asx",{"children":[["ticker","NYR","d"],{"children":["__PAGE__",{},[["$L1",["$","div",null,{"className":"space-y-12","children":[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$2"}}],["$","section",null,{"className":"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]","children":[["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"Health Care"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":["Nyrada Inc."," (","NYR",")"]}],["$","p",null,{"className":"mt-4 text-sm text-slate-300","children":"Nyrada Inc. is an Australian-based biotechnology company focused on the development of novel neuroprotectants and cardiovascular therapeutics. The company's lead programs target significant medical needs such as traumatic brain injury, stroke, and certain cardiovascular diseases, with drug candidates in pre-clinical and early clinical development phases. Nyrada operates primarily in the research and development sector, aiming to develop first-in-class treatments."}],["$","div",null,{"className":"mt-6 grid gap-4 sm:grid-cols-2","children":[["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Market Cap"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"A$225M"}]]}],["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Shares on Issue"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"N/A"}]]}]]}],["$","div",null,{"className":"mt-6 flex flex-wrap gap-3 text-xs text-slate-400","children":[["$","a",null,{"href":"","className":"rounded-full border border-white/10 px-3 py-1","children":"Company Website"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"AI coverage updated hourly"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"Data from ASX filings"}]]}]]}],["$","$L3",null,{"ticker":"NYR"}],["$","section",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"AI Analysis"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm text-slate-300","children":[["$","p","Nyrada Inc. (ASX: NYR) is currently an early-stage biotechnology company, with its primary assets being its intellectual property and drug candidate pipeline. Its lead compounds, NYR-BI03 (for brain injury) and NYR-CV01 (for cardiovascular disease), are progressing through pre-clinical and Phase 1 clinical trial stages, which are crucial but highly speculative phases of drug development. The company's financial position is typical of a pre-revenue biotech, heavily reliant on capital raises to fund extensive research and development expenses, making careful cash management and successful trial progression critical. As a micro-cap with a market cap of A$225M, its valuation is largely driven by future potential rather than current earnings.",{"children":"Nyrada Inc. (ASX: NYR) is currently an early-stage biotechnology company, with its primary assets being its intellectual property and drug candidate pipeline. Its lead compounds, NYR-BI03 (for brain injury) and NYR-CV01 (for cardiovascular disease), are progressing through pre-clinical and Phase 1 clinical trial stages, which are crucial but highly speculative phases of drug development. The company's financial position is typical of a pre-revenue biotech, heavily reliant on capital raises to fund extensive research and development expenses, making careful cash management and successful trial progression critical. As a micro-cap with a market cap of A$225M, its valuation is largely driven by future potential rather than current earnings."}],["$","p","The growth outlook for Nyrada hinges on the successful advancement of its drug candidates through clinical trials and the achievement of significant data milestones. Upcoming catalysts include the commencement and completion of Phase 1 clinical trials for its lead programs, announcement of safety and pharmacokinetic data, and any subsequent progression into later-stage trials. Strategic direction involves exploring potential licensing or partnership opportunities with larger pharmaceutical companies once compelling clinical data emerges, which could provide non-dilutive funding and accelerate commercialization. The high-risk, high-reward nature of biotech investing means successful trial outcomes could lead to substantial value creation, while setbacks could significantly impact the share price.",{"children":"The growth outlook for Nyrada hinges on the successful advancement of its drug candidates through clinical trials and the achievement of significant data milestones. Upcoming catalysts include the commencement and completion of Phase 1 clinical trials for its lead programs, announcement of safety and pharmacokinetic data, and any subsequent progression into later-stage trials. Strategic direction involves exploring potential licensing or partnership opportunities with larger pharmaceutical companies once compelling clinical data emerges, which could provide non-dilutive funding and accelerate commercialization. The high-risk, high-reward nature of biotech investing means successful trial outcomes could lead to substantial value creation, while setbacks could significantly impact the share price."}]]}]]}],["$","div",null,{"className":"grid gap-6 lg:grid-cols-2","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-emerald-300","children":"Bull Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Positive safety and efficacy data from ongoing or planned Phase 1/2 clinical trials for lead candidates (e.g., NYR-BI03 for brain injury), demonstrating clear therapeutic potential.",{"children":["â€¢ ","Positive safety and efficacy data from ongoing or planned Phase 1/2 clinical trials for lead candidates (e.g., NYR-BI03 for brain injury), demonstrating clear therapeutic potential."]}],["$","li","Successful execution of a strategic partnership or licensing agreement with a major pharmaceutical company for one of its pipeline assets, providing significant non-dilutive funding and validation.",{"children":["â€¢ ","Successful execution of a strategic partnership or licensing agreement with a major pharmaceutical company for one of its pipeline assets, providing significant non-dilutive funding and validation."]}],["$","li","Rapid progression of drug candidates through regulatory pathways, potentially securing Fast Track or Orphan Drug designations, accelerating development and market entry.",{"children":["â€¢ ","Rapid progression of drug candidates through regulatory pathways, potentially securing Fast Track or Orphan Drug designations, accelerating development and market entry."]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-red-300","children":"Bear Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Unfavorable or inconclusive results from clinical trials, particularly regarding safety or efficacy endpoints, leading to delays or discontinuation of development programs.",{"children":["â€¢ ","Unfavorable or inconclusive results from clinical trials, particularly regarding safety or efficacy endpoints, leading to delays or discontinuation of development programs."]}],["$","li","Failure to secure sufficient capital through equity raises or partnerships to fund ongoing and future clinical trials, potentially diluting existing shareholders or halting development.",{"children":["â€¢ ","Failure to secure sufficient capital through equity raises or partnerships to fund ongoing and future clinical trials, potentially diluting existing shareholders or halting development."]}],["$","li","Intense competition from larger pharmaceutical companies developing similar treatments, or regulatory setbacks that delay trial progression or market approval.",{"children":["â€¢ ","Intense competition from larger pharmaceutical companies developing similar treatments, or regulatory setbacks that delay trial progression or market approval."]}]]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Market Sentiment"}],["$","div",null,{"className":"mt-4 flex items-center gap-3","children":[["$","span",null,{"className":"inline-flex items-center gap-1.5 rounded-full border px-3 py-1 text-sm font-semibold bg-yellow-500/10 border-yellow-500/30 text-yellow-400","children":["ðŸŸ¡"," ","Mixed"]}],["$","span",null,{"className":"text-xs text-slate-500","children":["Score: ","","0.00"]}]]}],["$","div",null,{"className":"mt-4","children":[["$","div",null,{"className":"flex justify-between text-[10px] uppercase tracking-widest text-slate-500","children":[["$","span",null,{"children":"Bearish"}],["$","span",null,{"children":"Bullish"}]]}],["$","div",null,{"className":"relative mt-1 h-2 rounded-full bg-ink-900/60","children":[["$","div",null,{"className":"absolute left-1/2 top-0 h-full w-px bg-slate-600"}],["$","div",null,{"className":"absolute top-0 h-full w-2 rounded-full bg-yellow-500","style":{"left":"calc(50% - 4px)"}}]]}]]}],["$","div",null,{"className":"mt-4 flex gap-4 text-xs","children":[["$","span",null,{"className":"text-emerald-400","children":["â–² ",0," bullish"]}],["$","span",null,{"className":"text-red-400","children":["â–¼ ",0," bearish"]}],["$","span",null,{"className":"text-slate-500","children":[3," neutral"]}]]}],["$","p",null,{"className":"mt-1 text-xs text-slate-500","children":["Based on ",3," social post","s"]}],["$","div",null,{"className":"mt-4 space-y-2","children":[["$","p",null,{"className":"text-xs uppercase tracking-widest text-slate-500","children":"Recent mentions"}],[["$","div","0",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs","children":[["$","div",null,{"className":"flex items-center gap-2","children":[["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400","children":"hotcopper"}],["$","span",null,{"className":"text-slate-500","children":"2026-02-05"}],["$","span",null,{"className":"text-slate-400","children":"â€”"}]]}],["$","p",null,{"className":"mt-1.5 text-slate-300","children":"Informational post about NYR, INC"}]]}],["$","div","1",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs","children":[["$","div",null,{"className":"flex items-center gap-2","children":[["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400","children":"hotcopper"}],["$","span",null,{"className":"text-slate-500","children":"2026-02-05"}],["$","span",null,{"className":"text-slate-400","children":"â€”"}]]}],["$","p",null,{"className":"mt-1.5 text-slate-300","children":"Informational post about NYR, INC"}]]}],["$","div","2",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs","children":[["$","div",null,{"className":"flex items-center gap-2","children":[["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400","children":"hotcopper"}],["$","span",null,{"className":"text-slate-500","children":"2026-02-05"}],["$","span",null,{"className":"text-slate-400","children":"â€”"}]]}],["$","p",null,{"className":"mt-1.5 text-slate-300","children":"Informational post about NYR, INC"}]]}]]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Recent Announcements"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","0",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Cleansing Statement"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"5 Feb 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Capital Structure"}]]}],""]}],["$","div","1",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Application for quotation of securities - NYR"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"5 Feb 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Capital Structure"}]]}],""]}],["$","div","2",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Investor Update Webinar"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"4 Feb 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Progress Report"}]]}],""]}],["$","div","3",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Nyrada Phase IIa Clinical Trial Factsheet"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"4 Feb 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Progress Report"}]]}],""]}],["$","div","4",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Change in substantial holding - Matt Corp WA PL"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"29 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Substantial Holder"}]]}],""]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"FAQs"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","What does NYR do?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What does NYR do?"}],["$","p",null,{"className":"text-slate-400","children":"Nyrada Inc. is a biotechnology company developing novel drug candidates for serious medical conditions. Their primary focus areas are neuroprotection, with a lead program for traumatic brain injury and stroke, and cardiovascular disease, addressing unmet medical needs with potential first-in-class treatments."}]]}],["$","div","Is NYR a good investment?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"Is NYR a good investment?"}],["$","p",null,{"className":"text-slate-400","children":"Investing in Nyrada is considered highly speculative due to its early-stage drug development pipeline and pre-revenue status. It offers significant upside potential if its clinical trials prove successful and lead to commercialization or partnerships, but also carries high risks of failure common to the biotech sector. Investors should be prepared for volatility and the possibility of substantial capital loss."}]]}],["$","div","What drives NYR's share price?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What drives NYR's share price?"}],["$","p",null,{"className":"text-slate-400","children":"Nyrada's share price is primarily driven by news related to its clinical trial progress, such as commencement of new trial phases, interim or final data readouts, and regulatory milestones (e.g., ethics approvals, IND filings). Other key drivers include announcements of capital raises, strategic partnerships or licensing agreements, and general investor sentiment towards the biotechnology sector and specific therapeutic areas."}]]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-semibold","children":"Key Metrics"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Share Price"}],["$","span",null,{"className":"font-semibold","children":["A$","0.82"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"1Y Performance"}],["$","span",null,{"className":"font-semibold text-emerald-400","children":["662.8","%"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Market Cap"}],["$","span",null,{"className":"font-semibold","children":"A$225M"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Shares on Issue"}],["$","span",null,{"className":"font-semibold","children":"N/A"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Sector"}],["$","span",null,{"className":"font-semibold","children":"Health Care"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"IPO Date"}],["$","span",null,{"className":"font-semibold","children":"16/01/2020"}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Compare ASX Brokers"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Find the best trading platform for your needs. We review fees, features, and research tools."}],["$","div",null,{"className":"mt-4 grid gap-3 sm:grid-cols-2","children":[["$","div","AlphaTrade",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"AlphaTrade"}],["$","p",null,{"className":"text-xs text-slate-400","children":"$$0 brokerage on ETFs"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","MarketPilot",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"MarketPilot"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Advanced research suite"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","Coastline",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"Coastline"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Low FX fees"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","Harbour",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"Harbour"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Pro-level charting"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"Sponsored links. We may receive compensation if you open an account."}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Related Stocks"}],["$","div",null,{"className":"mt-4 space-y-4","children":[["$","$L4",null,{"href":"/asx/CSL","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["CSL",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"CSL Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","181.24"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-27.3","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$88.2B"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L4",null,{"href":"/asx/PNV","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["PNV",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Polynovo Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.99"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-13.1","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$670M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L4",null,{"href":"/asx/1AD","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["1AD",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Adalta Limited"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.01"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-25.6","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$11M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children","$6","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},[["$","html",null,{"lang":"en","className":"__variable_6d343d __variable_49a339","children":[["$","head",null,{"children":["$","link",null,{"rel":"icon","href":"/logo.svg","type":"image/svg+xml"}]}],["$","body",null,{"className":"min-h-screen bg-ink-900 text-slate-100","children":["$","div",null,{"className":"grid-glow min-h-screen","children":[["$","header",null,{"className":"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur","children":[["$","div",null,{"className":"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8","children":[["$","$L4",null,{"href":"/","className":"flex items-center gap-3","children":[["$","$L8",null,{"src":"/logo.svg","alt":"ASX Desk","width":140,"height":40,"className":"h-10 w-auto","priority":true}],["$","span",null,{"className":"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline","children":"Research Terminal"}]]}],["$","nav",null,{"className":"hidden items-center gap-6 text-sm text-slate-300 md:flex","children":[["$","$L4","/",{"href":"/","className":"transition hover:text-white","children":"Home"}],["$","$L4","/screener",{"href":"/screener","className":"transition hover:text-white","children":"Screener"}],["$","$L4","/sectors/materials",{"href":"/sectors/materials","className":"transition hover:text-white","children":"Sectors"}],["$","$L4","/news",{"href":"/news","className":"transition hover:text-white","children":"News"}],["$","$L4","/compare/BHP-vs-RIO",{"href":"/compare/BHP-vs-RIO","className":"transition hover:text-white","children":"Compare"}],["$","$L4","/about",{"href":"/about","className":"transition hover:text-white","children":"About"}]]}],["$","div",null,{"className":"hidden items-center gap-3 md:flex","children":[["$","$L9",null,{}],["$","button",null,{"className":"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20","children":"Premium Research"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400","children":"Open Account"}]]}]]}],["$","div",null,{"className":"flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden","children":[["$","div",null,{"className":"flex-1","children":["$","$L9",null,{}]}],["$","$L4",null,{"href":"/screener","className":"shrink-0 text-xs text-blue-300","children":"Screener"}]]}]]}],["$","main",null,{"className":"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8","children":["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":["$","div",null,{"className":"flex min-h-[60vh] flex-col items-center justify-center text-center","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"404"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":"Page not found"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"We couldn't locate that ASX page. Try searching a ticker or visit the homepage."}],["$","$L4",null,{"href":"/","className":"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white","children":"Back to Home"}]]}],"notFoundStyles":[],"styles":null}]}],["$","footer",null,{"className":"border-t border-white/10 bg-ink-800/60","children":[["$","div",null,{"className":"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8","children":[["$","div",null,{"children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"ASX Desk"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools."}],["$","div",null,{"className":"mt-4 flex gap-3","children":[["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}],["$","button",null,{"className":"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300","children":"Download Media Kit"}]]}]]}],["$","div",null,{"className":"grid grid-cols-2 gap-6 text-sm text-slate-400","children":[["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Platform"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L4",null,{"href":"/screener","className":"hover:text-white","children":"Screener"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/news","className":"hover:text-white","children":"News & Commentary"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/about","className":"hover:text-white","children":"About"}]}]]}]]}],["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Sectors"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/materials","className":"hover:text-white","children":"Materials"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/financials","className":"hover:text-white","children":"Financials"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/health care","className":"hover:text-white","children":"Health Care"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/information technology","className":"hover:text-white","children":"Information Tech"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/energy","className":"hover:text-white","children":"Energy"}]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h4",null,{"className":"font-semibold","children":"Weekly Alpha Briefing"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox."}],["$","div",null,{"className":"mt-4 flex flex-col gap-3 sm:flex-row","children":[["$","input",null,{"type":"email","placeholder":"you@example.com","className":"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Subscribe"}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"By subscribing you agree to receive marketing updates. Unsubscribe anytime."}]]}]]}],["$","div",null,{"className":"border-t border-white/10 py-6 text-center text-xs text-slate-500","children":["$","p",null,{"children":"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results."}]}]]}]]}]}]]}],null],null],[[["$","link","0",{"rel":"stylesheet","href":"/_next/static/css/092e787b67da2b4e.css","precedence":"next","crossOrigin":"$undefined"}]],[null,"$La"]]]]]
a:[["$","meta","0",{"name":"viewport","content":"width=device-width, initial-scale=1"}],["$","meta","1",{"charSet":"utf-8"}],["$","title","2",{"children":"NYR share price, analysis & company profile - Nyrada Inc. | ASX Desk"}],["$","meta","3",{"name":"description","content":"Latest NYR share price overview, what Nyrada Inc. does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","link","4",{"rel":"canonical","href":"https://asxdesk.com/asx/NYR/"}],["$","meta","5",{"property":"og:title","content":"NYR share price, analysis & company profile - Nyrada Inc."}],["$","meta","6",{"property":"og:description","content":"Latest NYR share price overview, what Nyrada Inc. does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","7",{"property":"og:url","content":"https://asxdesk.com/asx/NYR/"}],["$","meta","8",{"property":"og:type","content":"article"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"NYR share price, analysis & company profile - Nyrada Inc."}],["$","meta","11",{"name":"twitter:description","content":"Latest NYR share price overview, what Nyrada Inc. does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","12",{"name":"next-size-adjust"}]]
1:null
